Cases & Deals

AbbVie successfully faces off with Amgen in patent interference involving buffer-free antibody formulations

Clients AbbVie, Inc.

Jones Day represented AbbVie, Inc. in a patent interference against Amgen, Inc. before the PTAB involving the parties' applications/patents generally related to buffer-free antibody formulations, including formulations to adalimumab, marketed as Humira®. On December 15, 2017, Gokarn (Amgen) conceded priority as to the invention in dispute. As a result, on December 20, 2017, the PTAB entered judgement against Gokarn (Amgen) in favor of Fraunhofer (AbbVie).

Fraunhofer (AbbVie) v. Gokarn (Amgen), Patent Interference No. 106,057 (PTAB 2016)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.